LXEO Lexeo Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Lexeo Therapeutics, Inc. (LXEO) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 30, 2026, a 10-Q quarterly report filed on May 11, 2026, an 8-K current report filed on June 29, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Lexeo Therapeutics, Inc. (LXEO) (SEC CIK 1907108), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on Lexeo Therapeutics, Inc.
Ask AI about LXEO filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting LXEO positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on LXEO.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate LXEO share value held by 13F filers tracked by SignalX, by quarter.
- Goldman Sachs Group+1.17M (+149%)
- Millennium Management+704.8K (+78%)
- State Street Corp+380.5K (+12%)
- Bank of America Corp+331.2K (+207%)
- Morgan Stanley+262.7K (+187%)
- D.E. Shaw & Co449.7K (-94%)
- Two Sigma Investments218.9K (-55%)
- Wells Fargo & Co45.7K (-65%)
- BNY Mellon7.8K (-5%)
- Citigroup2.0K (-13%)
- Vanguard Group Inc−3.89M
- Invesco Ltd−463.0K
- Ameriprise Financial−243.3K
- Renaissance Technologies LLC−217.8K
- JPMorgan Chase & Co−29.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 128 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest LXEO SEC filings in 2026?
Lexeo Therapeutics, Inc. (LXEO) has filed a 10-K annual report on March 30, 2026, a 10-Q quarterly report on May 11, 2026, an 8-K current report on June 29, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did LXEO file its most recent 10-K annual report?
Lexeo Therapeutics, Inc. (LXEO) filed its most recent 10-K annual report on March 30, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view LXEO 10-Q quarterly reports?
Lexeo Therapeutics, Inc. (LXEO)'s most recent 10-Q quarterly report was filed on May 11, 2026. SignalX displays every LXEO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has LXEO filed recently?
Lexeo Therapeutics, Inc. (LXEO)'s most recent 8-K was filed on June 29, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find LXEO insider trading activity (Form 4)?
SignalX aggregates every LXEO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does LXEO file with the SEC?
Lexeo Therapeutics, Inc. (LXEO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LXEO filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Lexeo Therapeutics, Inc. (LXEO).
What is LXEO's SEC CIK number?
Lexeo Therapeutics, Inc. (LXEO)'s SEC CIK (Central Index Key) number is 1907108. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1907108 to look up all LXEO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of Lexeo Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 28+ filings.